A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer

Inclusion Criteria:

Histologically confirmed metastatic 1L Stage IV non-small cell lung cancer (NSCLC) of squamous or nonsquamous histology
No prior systemic anti-cancer treatment given as primary therapy for advanced or metastatic NSCLC
Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
A formalin-fixed, paraffin-embedded (FFPE) tumor tissue block or a minimum of 20 unstained slides of tumor tissue obtained during screening or prior to enrollment
Life expectancy of at least 3 months at the time of first dose

Exclusion Criteria:

Participants with epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or c-ros oncogene 1 (ROS-1) mutations which are sensitive to available targeted inhibitor therapy. Participants with nonsquamous histology and unknown EGFR, ALK, or ROS-1 status are also excluded
Participants with known B-rapidly accelerated fibrosarcoma proto-oncogene (BRAF) V600E mutations that are sensitive to available targeted inhibitor therapy. Participants with unknown or indeterminate BRAF mutation status are eligible.
Untreated central nervous system metastases
Leptomeningeal metastases (carcinomatous meningitis)
Concurrent malignancy requiring treatment
Active, known, or suspected autoimmune disease
Interstitial lung disease
Uncontrolled or significant cardiovascular disease

Other protocol-defined inclusion/exclusion criteria apply